Malignant Soft Tissue Neoplasm of Uncertain Differentiation

Malignant Soft Tissue Neoplasm of Uncertain Differentiation — Trials · CancerIndex

Clinical trials

Registered studies

186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 66
Recruiting: 40
Ph III recruiting: 2
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 42.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (29)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07695311	EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT	not yet recruiting	Phase 1	24	Rabi HannaOTHER	1	Sep 17, 2026	clinicaltrials
NCT07713732	TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors	not yet recruiting	Phase 1	120	Treeline Biosciences, Inc.INDUSTRY	1	Jul 28, 2026	clinicaltrials
NCT06748872